News
Farnesoid X receptor (FXR) has been previously identified as an important drug target for nonalcoholic steatohepatitis (NASH) and other related diseases, with GW-4064 being the first nonsteroidal FXR ...
Researchers from Guangdong Pharmaceutical University and affiliated organizations have discovered novel farnesoid X receptor (FXR) agonists as candidates for the treatment of nonalcoholic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback